Tada

Thanks for your comprehensive analysis and computing the Rvx costs to get to market of 120mil.

I errored in my last post.

"whether or not RVX will retain any future interest in Zen-3694 " should have stated "whether or not ZCC will retain any future interest in Zen-3694"  - you answered my question, ie., ZCC will retain an 8% royalty on future net sales of Zen-3694. (per slide 17)

The following are my rough takes on slide 17 of the Zenith AGM - perhaps wishful thinking:

1. ZCC sells 50% of Rvx Royalty Preferred Shares. 83bil x .7 = net global sales of 58bil x 50% = 29bil x 9% (est) 2.6 future royalties with a discounted npv of 5%  yielding proceeds of 130mil. ZCC retains 50% of royalty preferred shares.

2. ZCC sells ZEN-3694 IP for 300-500mil cash + an 8% royalty on future net global sales of ZEN-3694 and retains a 100% interest in Rvx Royalty Preferred Shares. ZCC dividends excess cash to shareholders ( sales proceeds less corporate liabilities less cost of bom2 and long-Covid trials).

just my take on the possiblities

Chicagoest